Aug 20, 2026 · 20 min
Target, Moderna and AI Face Three Very Different Growth Tests
Behind The Most Exciting Stock Pop In Years!
The episode connects a retailer’s uncertain recovery, a biotech breakthrough and worsening AI economics to the question of whether market enthusiasm can last.
- 1Target’s improving sales and digital strategy face tariff distortion and formidable competition from Walmart and Amazon.
- 2Moderna’s personalized mRNA cancer-vaccine results could broaden its business beyond vaccines and explain the stock’s dramatic surge.
- 3OpenAI’s slower growth and faster-rising losses sharpen questions about pricing, market share and a potential IPO race with Anthropic.
Don't miss
Moderna’s major personalized cancer-vaccine results produce a dramatic market reaction and reshape the company’s possible future in oncology.
The brief
Lou Whiteman and Travis Holy examine Target’s improved sales and same-store performance, while warning that a tariff refund inflated earnings and may make the turnaround look stronger than it is.
Target’s long-term case depends on more than a better quarter: the hosts weigh its pricing, dividend, digital operations and Shipt integration against Walmart and Amazon.
Moderna’s phase three personalized mRNA cancer-vaccine results trigger a dramatic stock surge, raising the possibility that the company could expand from vaccines into oncology.
The AI discussion turns to OpenAI’s 18% quarter-over-quarter growth, faster-rising operating losses and lower API prices, which may signal investment—or worsening economics.
OpenAI and Anthropic sit inside a wider investment cycle spanning hyperscalers, neoclouds and chip companies; future S-1 filings could clarify costs, obligations and IPO prospects.
Featuring
OpenAI
Anthropic
ChatGPTListen to the full episode and explore every guest, topic, and moment on PodLume.